COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,184 Articles (22,713 medRxiv, 8,471 bioRxiv)

Most recent first Previous |  Page 896: Articles 8951-8960  | Next

Comparison of Rapid Antigen Tests' Performance between Delta (B.1.61.7; AY.X) and Omicron (B.1.1.529; BA1) Variants of SARS-CoV-2: Secondary Analysis from a Serial Home Self-Testing Study
Soni, A., Herbert, C., Filippaios, A., Broach, J., Colubri, A., Fahey, N., Woods, K., Nanavati, J., Wright, C., Orwig, T., Gilliam, K., Kheterpal, V., Suvarna, T., Nowak, C., Schrader, S., Lin, H., O'Connor, L., Pretz, C., Ayturk, D., Orvek, E., Flahive, J., Lazar, P., Shi, Q., Achenbach, C. J., Murphy, R. L., Robinson, M. L., Gibson, L., Stamegna, P., Hafer, N., Luzuriaga, K., Barton, B., Manabe, Y. C., McManus, D., RADx Clinical Studies Core Team, , Test Us At Home Investigators
10.1101/2022.02.27.22271090 — Posted: 2022-02-28 Discussion: Onsite
Design, Synthesis and Evaluation of Inhibitors of the SARS-CoV-2 nsp3 Macrodomain
Sherrill, L. M., Joya, E. E., Walker, A., Roy, A., Alhammad, Y. M., Atobatele, M., Wazir, S., Abbas, G., Keane, P., Zhuo, J., Leung, A., Johnson, D. K., Lehtio, L., Fehr, A., Ferraris, D. V.
10.1101/2022.02.27.482176 — Posted: 2022-02-28
Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2
Ohashi, H., Hishiki, T., Akazawa, D., Kim, K. S., Woo, J., Shionoya, K., Tsuchimoto, K., Iwanami, S., Moriyama, S., Kinoshita, H., Yamada, S., Kuroda, Y., Yamamoto, T., Kishida, N., Watanabe, S., Hasegawa, H., Ebihara, H., Suzuki, T., Maeda, K., Fukushi, S., Takahashi, Y., Iwami, S., Watashi, K.
10.1101/2022.02.27.482147 — Posted: 2022-02-28
An immunoPET probe to SARS-CoV-2 reveals early infection of the male genital tract in rhesus macaques
Madden, P. J., Thomas, Y., Blair, R. V., Samer, S., Doyle, M., Midkiff, C. C., Becker, M. E., Arif, M. S., McRaven, M. D., Simons, L. M., Carias, A. M., Martinelli, E., Lorenzo-Redondo, R., Hultquist, J. F., Villinger, F. J., Veazey, R. S., Hope, T. J.
10.1101/2022.02.25.481974 — Posted: 2022-02-28
A strategy to optimize the peptide-based inhibitors against different mutants of the spike protein of SARS-CoV-2
Priya, P., Basit, A., Bandyopadhyay, P.
10.1101/2022.02.27.482153 — Posted: 2022-02-28
Efficient Neutralization of SARS-CoV-2 Omicron and Other VOCs by a Broad Spectrum Antibody 8G3
Ma, H., Tseng, C.-T. K., Zong, H., Liao, Y., Ke, Y., Tang, H., Wang, L., Wang, Z., He, Y., Chang, Y., Wang, S., Drelich, A., Hsu, J., Tat, V., Yuan, Y., Wu, M., Liu, J., Yue, Y., Xu, W., Zhang, X., Wang, Z., Yang, L., Chen, H., Bian, Y., Zhang, B., Yin, H., Chen, Y., Zhang, E., Zhang, X., Gilly, J., Sun, T., Han, L., Xie, Y., Jiang, H., Zhu, J.
10.1101/2022.02.25.482049 — Posted: 2022-02-28
Drivers of adaptive evolution during chronic SARS-CoV-2 infections
Harari, S., Tahor, M., Rutsinsky, N., Meijer, S., Miller, D., Henig, O., Halutz, O., Levytskyi, K., Ben-Ami, R., Adler, A., Paran, Y., Stern, A.
10.1101/2022.02.17.22270829 — Posted: 2022-02-28
Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant
Dorabawila, V., Hoefer, D., Bauer, U. E., Bassett, M., Lutterloh, E., Rosenberg, E.
10.1101/2022.02.25.22271454 — Posted: 2022-02-28 Discussion: Onsite
Genomics of Post-Vaccination SARS-CoV-2 Infections During the Delta Dominated Second Wave of COVID-19 Pandemic, from Mumbai Metropolitan Region (MMR), India
Nilgiriwala, K. S., Kadam, P., Patel, G., Shaikh, A., Mestry, T., Vaswani, S., Sakthivel, S., Poojary, A., Gandhi, B., Rohra, S., Udwadia, Z., Oswal, V., Shah, D., Gomare, M., Sriraman, K., Mistry, N.
10.1101/2022.02.26.22271546 — Posted: 2022-02-27
Factors associated with the decay of anti-SARS-CoV-2 neutralizing antibodies among recipients of an adenoviral vector-based AZD1222 and a whole-virion inactivated (BBV152) vaccine in Chennai, India: a cross-sectional cohort study
Selvavinayagam, S. T., Yong, Y. K., Tan, H. Y., Zhang, Z.-Y., Subramanian, G., Rajeshkumar, M., Vasudevan, K., Jayapal, P., Narayanasamy, K., Ramesh, D., Palani, S., Larsson, M., Esaki Muthu, S., Raju, S.
10.1101/2022.02.26.22271097 — Posted: 2022-02-27

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).